CLAIMS

1. A salt of 1-[[(3S)-3-methyl-6-(4,4,4-trifluorobutoxy)-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylic acid.

2. The compound according to claim 1, wherein the salt is mono(4-hydroxybenzoate).

3. The compound according to claim 2, which is in crystal form.

4. The crystal according to claim 3, having, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of at least about 6.9, about 12.8, about 13.9, and about 24.7 degrees.

5. The crystal according to claim 3, having, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of at least about 5.4, about 6.9, about 13.9, about 18.1, about 19.4, about 19.8, about 20.9, and about 24.7 degrees.

6. The crystal according to claim 4 or 5, having, in a powder X-ray diffraction spectrum, no diffraction peak at diffraction angles (2θ) of about 11.3 and about 14.4 degrees.

7. The crystal according to any one of claims 3 to 6, having, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of about 5.4, about 6.9, about 10.3, about 12.8, about 13.9, about 15.0, about 15.3, about 15.9, about 16.6, about 16.8, about 18.1, about 19.4, about 19.8, about 20.9, about 21.8, about 22.7, about 23.6, about 24.7, about 25.4, about 25.8, about 26.3, about 26.7, about 27.6, about 27.8, about 30.3, about 33.4, and about 34.2 degrees.

8. The crystal according to any one of claims 3 to 7, characterized by a powder X-ray diffraction spectrum chart shown in Fig. 7.

9. The crystal according to any one of claims 3 to 8, having an endothermic peak with an onset temperature of about 150°C or a peak temperature of about 153°C in differential scanning calorimetry.

10. The crystal according to any one of claims 3 to 9, characterized by a differential scanning calorimetry chart shown in Fig. 8.

11. The crystal according to claim 3, having, in a powder X-ray diffraction spectrum, a diffraction peak at a diffraction angle (2θ) of at least about 11.3 degrees.

12. The crystal according to claim 3 or claim 11, having, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of at least about 5.6, about 11.3, about 13.2, about 15.9, about 16.9, about 18.8, about 22.7, and about 24.2 degrees.

13. The crystal according to claim 3, claim 11, or claim 12, having, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of about 5.6, about 7.0, about

7.9, about 11.3, about 12.3, about 13.2, about 13.9, about 15.9, about 16.9, about 17.4, about 17.9, about 18.4, about 18.8, about 19.4, about 19.9, about 20.4, about 21.0, about 21.2, about 21.9, about 22.7, about 23.2, about 23.4, about 24.2, about 25.2, about 26.5, about 27.5, about 29.1, about 29.8, about 30.5, and about 34.1 degrees.

14. The crystal according to any one of claim 3 or claims 11 to 13, characterized by a powder X-ray diffraction spectrum chart shown in Fig. 9.

15. The crystal according to any one of claim 3 or claims 11 to 14, having an endothermic peak with an onset temperature of about 154°C or a peak temperature of about 158°C in differential scanning calorimetry.

16. The crystal according to any one of claim 3 or claims 11 to 15, characterized by a differential scanning calorimetry chart shown in Fig. 10.

17. The compound according to claim 1, wherein the salt is a mono-tryptophan salt.

18. The compound according to claim 17, which is in crystal form.

19. The crystal according to claim 18, having, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of at least about 8.0, about 9.7, about 16.0, about 17.0, about 18.9, about 19.1, about 22.2, and about 24.6 degrees.

20. The crystal according to claim 18 or claim 19, having, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of about 8.0, about 9.7, about 12.8, about 15.6, about 16.0, about 16.6, about 17.0, about 17.3, about 17.6, about 18.2, about 18.6, about 18.9, about 19.1, about 19.6, about 20.9, about 21.3, about 21.7, about 21.9, about 22.2, about 22.6, about 23.4, about 23.8, about 24.6, about 25.3, about 25.7, about 26.2, about 26.6, about 27.1, about 27.4, about 27.9, about 28.2, about 28.7, about 29.1, about 29.9, about 30.2, about 30.9, about 32.0, about 32.2, about 32.5, about 33.1, about 34.1, about 34.5, and about 34.8 degrees.

21. The crystal according to any one of claims 18 to 20, characterized by a powder X-ray diffraction spectrum chart shown in Fig. 15.

22. The crystal according to any one of claims 18 to 21, having an endothermic peak with an onset temperature of about 178°C or a peak temperature of about 183°C in differential scanning calorimetry.

23. The crystal according to any one of claims 18 to 22, having an exothermic peak with an onset temperature of about 185°C or a peak temperature of about 187°C in differential scanning calorimetry.

24. The crystal according to any one of claims 18 to 23, characterized by a differential scanning calorimetry chart shown in Fig. 16.

25. The compound according to claim 1, wherein the salt is a hemisuccinate.

26. The compound according to claim 25, which is in crystal form.

27. The crystal according to claim 26, having, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of at least about 6.4, about 6.9, about 12.9, about 13.8, about 17.2, about 18.1, about 19.3, about 23.9, and about 24.3 degrees.

28. The crystal according to claim 26 or claim 27, having, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of about 6.1, about 6.4, about 6.9, about 12.9, about 13.8, about 16.6, about 17.2, about 18.1, about 18.3, about 18.7, about 19.3, about 19.9, about 20.5, about 20.7, about 21.0, about 21.4, about 21.9, about 22.1, about 22.7, about 23.0, about 23.6, about 23.9, about 24.3, about 24.6, about 25.2, about 25.8, about 26.0, about 27.4, about 27.5, about 27.8, about 28.7, about 29.5, about 30.2, about 30.5, about 30.8, about 31.3, about 31.7, about 32.3, about 32.5, about 33.8, about 34.1, about 34.5, and about 34.9 degrees.

29. The crystal according to any one of claims 26 to 28, characterized by a powder X-ray diffraction spectrum chart shown in Fig. 17.

30. The crystal according to any one of claims 26 to 29, having an endothermic peak with an onset temperature of about 111°C or a peak temperature of about 114°C in differential scanning calorimetry.

31. The crystal according to any one of claims 26 to 30, having an endothermic peak with an onset temperature of about 137°C or a peak temperature of about 140°C in differential scanning calorimetry.

32. The crystal according to any one of claims 26 to 31, characterized by a differential scanning calorimetry chart shown in Fig. 18.

33. A crystal of 1-[[(3S)-3-methyl-6-(4,4,4-trifluorobutoxy)-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylic acid.

34. The crystal according to claim 33, having, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of at least about 6.5, about 7.8, about 8.6, and about 11.6 degrees.

35. The crystal according to claim 33 or claim 34, having, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of about 6.5, about 7.8, about 8.6, about 11.6, about 13.0, about 13.1, about 15.2, about 15.8, about 17.0, about 17.3, about 18.8, about

18.9, about 19.3, about 20.9, about 21.1, about 21.3, about 22.8, about 23.3, about 23.6, about 23.8, about 24.0, about 24.9, about 25.8, about 26.4, about 27.1, about 27.9, about 29.8, about 30.4, about 30.7, about 31.6, about 32.0, and about 34.0 degrees.

36. The crystal according to any one of claims 33 to 35, characterized by a powder X-ray diffraction spectrum chart shown in Fig. 1.

37. The crystal according to any one of claims 33 to 36, having an endothermic peak with an onset temperature of about 128°C or a peak temperature of about 133°C in differential scanning calorimetry.

38. The crystal according to any one of claims 33 to 37, characterized by a differential scanning calorimetry chart shown in Fig. 2.

39. A pharmaceutical composition comprising the compound according to any one of claims 1 to 38 and a pharmaceutically acceptable carrier.

40. The pharmaceutical composition according to claim 39, which is a preventive and/or therapeutic agent for a $S1P_5$-mediated disease.

41. The pharmaceutical composition according to claim 40, wherein the $S1P_5$-mediated disease is a neurodegenerative disease.

42. The pharmaceutical composition according to claim 41, wherein the neurodegenerative disease is multiple system atrophy or Parkinson's disease.

43. A preventive and/or therapeutic agent for a $S1P_5$-mediated disease, comprising the compound according to any one of claims 1 to 38.

~~44. A method for preventing and/or treating a $S1P_5$-mediated disease, comprising administering an effective amount of the compound according to any one of claims 1 to 38 to a mammal.~~

~~45~~44. A compound according to any one of claims 1 to 38 for use in prevention and/or treatment of a $S1P_5$-mediated disease.

~~46~~45. Use of the compound according to any one of claims 1 to 38 in the manufacture of a medicament for ~~for producing a preventive~~the prevention and/or ~~therapeutic agent for~~treatment of a $S1P_5$-mediated disease.